Through partnerships with biotech venture incubators like LabCentral in Boston, Billorian invests in promising pharmaceutical research. Focused on cancer therapies, genetic treatments, and diagnostics, investments yield returns through pharmaceutical licensing deals and early market approvals. Clients benefit from contractual participation in startup exits and licensing revenues.